Learn how protein-level evidence can augment or replace genomic inference at critical drug development decision points.
On the use of comprehensive tumor proteomics to identify cancer targets and biology hiding beyond DNA and RNA.
Query target protein expression across 15+ normal human tissues to establish baseline biological context for drug development.
Introducing SurfaceSeek™, SignalingSeek™, ImmuneSeek™, and ResistanceSeek™ – optimized for fresh & FFPE human tumors.
Enabling absolute quantitation of APOE4, BD-pTau217, Aβ42, GFAP, and NfL in a single multiplexed assay.
On closing the gap between molecular measurement & clinical meaning, rapidly extracting actionable biological signals.
PharmaShots delves into Sapient’s mission to transform multi-omics research through innovation & world-class partnerships.
Enabling measure of 10K+ proteins in FFPE tissue & tumors and multi-omic molecular mapping of tumor biology.
The innovations enhance how MS data is processed, filtered & interpreted across large-scale biological datasets.
Bridging the gap from large-scale omics data generation to deep characterization of disease & treatment biomarkers.
Detailing the rLC-MS method & its use to predict clinically relevant physiological states at scale in human populations.
Exploring key innovations have converged to transform the utility of proteomics in drug discovery & development.
